Pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Aurobindo Pharma has informed about Investor Grievance Report for the Quarter ended 31.03.2017.
The above information is a part of company’s filings submitted to BSE.